Literature DB >> 17135460

Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography.

J T O'Brien1, S J Colloby, S Pakrasi, E K Perry, S L Pimlott, D J Wyper, I G McKeith, E D Williams.   

Abstract

BACKGROUND: Loss of the alpha4beta2 nicotinic receptor subtype is found at autopsy in Alzheimer's disease.
OBJECTIVE: To investigate in vivo changes in this receptor using single-photon-emission CT (SPECT) with 123I-5-iodo-3-[2(S)-2-azetidinylmethoxy] pyridine (5IA-85380), a novel nicotinic acetylcholine receptor ligand which binds predominantly to the alpha4beta2 receptor.
METHODS: 32 non-smoking subjects (16 with Alzheimer's disease and 16 normal elderly controls) underwent 123I-5IA-85380 and perfusion (99mTc-hexamethylenepropyleneamine oxime (HMPAO)) SPECT scanning. Region of interest analysis was performed with cerebellar normalisation.
RESULTS: Significant bilateral reductions in nicotinic receptor binding were identified in frontal (left, p = 0.004; right, p = 0.002), striatal (left, p = 0.004; right, p = 0.003), right medial temporal (p = 0.04) and pons (p<0.001) in patients with AD compared to controls. There were no significant correlations with clinical or cognitive measures. The pattern of nicotinic binding significantly differed from that of perfusion in both patients with AD and controls. Both 123I-5IA-85380 and 99mTc-HMPAO SPECT imaging demonstrated similar diagnostic performance in correctly classifying controls and patients with AD.
CONCLUSION: Using 123I-5IA-85380 SPECT we found changes consistent with significant reductions in the nicotinic alpha4beta2 receptor in cortical and striatal brain regions. This method could facilitate diagnosis and may be useful for monitoring progression of the disease and response to treatment in patients with AD and related diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135460      PMCID: PMC2077777          DOI: 10.1136/jnnp.2006.108209

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  38 in total

1.  Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging.

Authors:  K A Jobst; L P Barnetson; B J Shepstone
Journal:  Int Psychogeriatr       Date:  1998-09       Impact factor: 3.878

2.  Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies.

Authors:  P D Acton; K J Friston
Journal:  Eur J Nucl Med       Date:  1998-07

3.  Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains.

Authors:  U Warpman; A Nordberg
Journal:  Neuroreport       Date:  1995-11-27       Impact factor: 1.837

Review 4.  Nicotinic receptor abnormalities in Alzheimer's disease.

Authors:  J Court; C Martin-Ruiz; M Piggott; D Spurden; M Griffiths; E Perry
Journal:  Biol Psychiatry       Date:  2001-02-01       Impact factor: 13.382

5.  Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease.

Authors:  Z Z Guan; X Zhang; R Ravid; A Nordberg
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

6.  Autoradiographic comparison of [3H](-)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease.

Authors:  W Sihver; P G Gillberg; A L Svensson; A Nordberg
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

7.  Delusions associated with elevated muscarinic binding in dementia with Lewy bodies.

Authors:  C Ballard; M Piggott; M Johnson; N Cairns; R Perry; I McKeith; E Jaros; J O'Brien; C Holmes; E Perry
Journal:  Ann Neurol       Date:  2000-12       Impact factor: 10.422

Review 8.  The role of nicotinic acetylcholine receptors in Alzheimer's disease.

Authors:  Salvatore Oddo; Frank M LaFerla
Journal:  J Physiol Paris       Date:  2006-01-30

Review 9.  Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.

Authors:  Edward D Levin; F Joseph McClernon; Amir H Rezvani
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 10.  Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia.

Authors:  Nadine J Dougall; Sjoerd Bruggink; Klaus P Ebmeier
Journal:  Am J Geriatr Psychiatry       Date:  2004 Nov-Dec       Impact factor: 4.105

View more
  20 in total

1.  Quantitative Molecular Imaging of Neuronal Nicotinic Acetylcholine Receptors in the Human Brain with A-85380 Radiotracers.

Authors:  Shahrdad Lotfipour; Mark Mandelkern; Arthur L Brody
Journal:  Curr Med Imaging Rev       Date:  2011-05-01

Review 2.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

3.  Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Authors:  James Robert Brasić; Yun Zhou; John L Musachio; John Hilton; Hong Fan; Andrew Crabb; Christopher J Endres; Melvin J Reinhardt; Ahmet S Dogan; Mohab Alexander; Olivier Rousset; Marika A Maris; Jeffrey Galecki; Ayon Nandi; Dean F Wong
Journal:  Synapse       Date:  2009-04       Impact factor: 2.562

4.  Construction of SH-EP1-alpha4beta2-hAPP695 cell line and effects of nicotinic agonists on beta-amyloid in the cells.

Authors:  Huizhen Nie; Zuoqing Li; Ronald J Lukas; Yinghua Shen; Li Song; Xin Wang; Ming Yin
Journal:  Cell Mol Neurobiol       Date:  2007-10-03       Impact factor: 5.046

5.  Abnormal short latency afferent inhibition in early Alzheimer's disease: a transcranial magnetic demonstration.

Authors:  Raffaele Nardone; Jürgen Bergmann; Martin Kronbichler; Alexander Kunz; Stefanie Klein; Francesca Caleri; Frediano Tezzon; Gunther Ladurner; Stefan Golaszewski
Journal:  J Neural Transm (Vienna)       Date:  2008-10-08       Impact factor: 3.575

6.  Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.

Authors:  J R Ellis; P J Nathan; V L Villemagne; R S Mulligan; T Saunder; K Young; C L Smith; J Welch; M Woodward; K A Wesnes; G Savage; C C Rowe
Journal:  Psychopharmacology (Berl)       Date:  2008-10-24       Impact factor: 4.530

Review 7.  Acetylcholine receptors in dementia and mild cognitive impairment.

Authors:  Osama Sabri; Kai Kendziorra; Henrike Wolf; Hermann-Josef Gertz; Peter Brust
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

8.  Evaluation of the Relationship Between Cognitive Impairment, Glycometabolism, and Nicotinic Acetylcholine Receptor Deficits in a Mouse Model of Alzheimer's Disease.

Authors:  Yuki Matsuura; Masashi Ueda; Yusuke Higaki; Kohei Sano; Hideo Saji; Shuichi Enomoto
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

Review 9.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

10.  Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT.

Authors:  Effie M Mitsis; Kelly P Cosgrove; Julie K Staley; Frederic Bois; Erin B Frohlich; Gilles D Tamagnan; Kristina M Estok; John P Seibyl; Christopher H van Dyck
Journal:  Neurobiol Aging       Date:  2008-02-01       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.